HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eyles, D. E. Articles by Coleman, N. Search for Related Content PubMed PubMed Citation Articles by Eyles, D. E. Articles by Coleman, N.

The Relative Activity of the Common Sulfonamides against Experimental Toxoplasmosis in the Mouse

Defining the effective dose as the dose producing 10-day survival of mice inoculated with 20,000 Toxoplasma organisms, median effective doses of the common sulfonamides were measured under uniform conditions, as follows:

Since the pyrimidine derivatives, sulfadiazine, sulfamerazine and sulfamethazine, had the smallest effective dosages and are known to be the least toxic of the sulfonamides tested, it was concluded that these drugs are the most efficient antitoxoplasmic agents.

Although MED's were low, increasing the amount of drug administered did not result in all animals surviving. With the highest dosages only about two-thirds survived 10 days.

Blood chemistry studies showed that sulfadiazine, sulfamerazine, and sulfamethazine are effective in mice at blood levels much below those safely attainable in man.

About one-fourth of the mice given a dosage of 0.063 per cent or more sulfadiazine in the diet survived for 42 days. A number of these animals were tested to see if cure (freedom from parasites) had been effected. In the majority of cases tissues from the surviving mice produced no infection when injected into clean recipient mice. Other surviving animals were reinoculated with Toxoplasma organisms and all of these proved susceptible and most died from five to seven days later.

This article has been cited by other articles:

				M. J. HOGAN Ocular Toxoplasmosis: Clinical and Laboratory Diagnosis; Evaluation of Immunologic Tests; Treatment Arch Ophthalmol, March 1, 1956; 55(3): 333 - 345. [Abstract] [PDF]